PositiveID Corporation (fka PSID)

[greaseyfingers]

Award-of-Phase II, Stage-1 Contract, subject to Gen-3 Analysis-of-Alternatives..

Unless DHS specifically defines for everyone, to whom it may concern, what the exact legal definition meaning is of their terminology phrase, Gen-3 Analysis of Alternatives, (AoA), actually means..

It leaves room for speculation, in the meantime, until we are Officially Informed..

greaseyfingers Tuesday, March 05, 2013 7:06:59 AM
Re: Robsct post# 6487 Post #6489 of 6699
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=85286818

Official Information from the Government's Website..

BioWatch Gen-3 Phase II, Stage1 Presolicitation and Draft Request for Proposal

Solicitation Number: HSHQDC-13-R-00026
Agency: Department of Homeland Security
Office: Office of the Chief Procurement Officer
Location: Office of Procurement Operations

Changed
Feb 08, 2013
1:35 pm

Solicitation Number:
HSHQDC-13-R-00026 Notice Type:

Modification/Amendment Synopsis:
Added: Feb 08, 2013 1:35 pm

The purpose of this update is to inform interested parties that posting of the draft RFP does not represent a commitment by the Government to release a final RFP or to award a contract.

The draft RFP is posted for purposes of obtaining industry comments and feedback on the proposed solicitation approach for fulfilling Phase II, Stage 1 requirements.

Award of a Phase II, Stage 1 contract will be subject to the outcome of a Gen-3 Analysis of Alternatives (AoA) initiated by the Department of Homeland Security in July 2012.

A decision on the Gen-3 program is projected in the fall of 2013
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
following completion of the Analysis of Alternatives, (AoA).
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Please continue to monitor FedBizOpps for additional updates.

Contracting Office Address:
Office of the Chief Procurement Officer
Washington, District of Columbia 20528
United States

Place of Performance:
Continental United States

United States

Primary Point of Contact.:
Carla Davis,
Contracting Officer
[e-mail]

https://www.fbo.gov/index?id=90399125fc575caa7b316dce773b1192
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

BioWatch Gen-3 Phase II, Stage1 Presolicitation and Draft Request for Proposal

Solicitation Number: HSHQDC-13-R-00026
Agency: Department of Homeland Security
Office: Office of the Chief Procurement Officer
Location: Office of Procurement Operations

Solicitation Number: HSHQDC-13-R-00026

Notice Type: Presolicitation

C.1.2. TWO STAGE PROCUREMENT

DHS plans to conduct a two-stage procurement for the Gen-3 Phase II acquisition using a competitive down-selection technique between stages.

Stage 1 will be for Performance Testing of candidate systems and

Stage 2 will be for Operational Test and Evaluation (OT&E), Detector Production, Deployment, Sustainment and Disposal.

The Government anticipates awarding multiple contracts for Stage 1.

However, only one contract will be awarded under Stage 2 after a competive down selection between stages.

At the conclusion of Stage 1 a separate solicitation will be issued for Stage 2 requirements.

Stage 2 will be a full and open competition.

As in Stage 1, Stage 2 offerors must also demonstrate a design maturity equivalent to that of Technology Readiness Level 7, or greater, as described in Section C.2.5. below.

In addition, they must provide an equivalent third-party data set as was generated during Stage 1.

DRAFT Request for Proposal: HSHQDC-13-R-00026
Type: Other (Draft RFPs/RFIs, Responses to Questions, etc..)
Posted Date: January 25, 2013

HSHQDC-13-R-00026_COVER_LETTER.pdf (132.85 Kb)
Description: Cover Letter: DRAFT Request for Proposal, HSHQDC-13-R-00026

HSHQDC-13-R-00026_DRAFT_RFP,_BioWatch_Gen-3_Phase_2_... (588.76 Kb)Download/View

HSHQDC-13-R-00026_DRAFT_RFP,_BioWatch_Gen3_Phase_2_Stage_1.pdfDescription: DRAFT Request for Proposal,

HSHQDC-13-R-00026 J.1_Cost_Pricing_Schedule.xls (35.50 Kb)
Description: ATTACHMENT J.1: Cost/Pricing Schedule

J.6_Question_and_Answer_Sheet.xlsx (11.64 Kb)
Description: ATTACHMENT J.6: Draft RFP Question and Answer Sheet

J.8_NonDisclosure_Agreement.pdf (32.19 Kb)
Description: ATTACHMENT J.8: BioWatch Non-Disclosure Agreement

J.10...Subcontracting_Plan_Checklist.pdf (632.32 Kb)
Description: ATTACHMENT J.10: Small Business Subcontracting Plan Checklist

Contracting Office Address:
Office of the Chief Procurement Officer
Washington, District of Columbia 20528
United States

Place of Performance:
Continental United States

https://www.fbo.gov/index?s=opportunity&mode=form&id=cd3f4aa9250b9d0e77118d4d5693c2a1&tab=core&_cview=0
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Robsct Tuesday, March 05, 2013 5:19:45 AM
Re: None Post #6487 of 6488
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=85285694

I'll post this again. According to DHS's timetable they want to award the big contract to produce and deploy Gen-3 this year.

The program was kicked off in 2007 and said to be scheduled for testing in 2008 with completion of the whole program in 2012. The article identifies the division of DHS as the same one that Caragol stated in the recent PR. It's the same testing phase...and it's now done.

"This is the two-pronged goal of research behind the Generation 3 BioWatch Program, which is funded by the Chemical and Biological Division at the Department of Homeland Security's (DHS) Science and Technology Directorate (S&T). "

http://www.dhs.gov/lab-box

"William J. Caragol, Chairman and CEO of PositiveID, stated, "We believe that PositiveID is well positioned for BioWatch Generation 3, as our M-BAND detection technology (Microfluidics-based BioAgent Autonomous Networked Detector) was the only system of its kind successfully demonstrated in the field as part of the DHS Science & Technology Directorate ("S&T") BAND (BioAgent Autonomous Networked Detector) Program. In October 2012, we issued a corporate update to our stockholders about the BioWatch program, stating that we were in discussions with strategic partners to manufacture and sell M-BAND, and reiterating our belief that the BioWatch program would soon begin to roll out."

http://finance.yahoo.com/news/positiveid-reports-issuance-draft-rfp-213000044.html